Tempest Therapeutics Advances Phase 3 Trial of TPST-1120 Combination for Hepatocellular Carcinoma
Key Insights
Tempest Therapeutics is conducting a Phase 3 clinical trial evaluating TPST-1120 combined with atezolizumab and bevacizumab versus standard care in patients with unresectable or metastatic hepatocellular carcinoma (search).
TPST-1120 is an orally administered competitive antagonist of PPARα (search) that aims to extend patient survival when combined with the current standard treatment regimen.
The randomized, quadruple-masked study is set to begin recruitment in November 2024, with collaboration from Hoffmann-La Roche highlighting its potential industry impact.
Tempest Therapeutics has initiated a pivotal Phase 3 clinical trial testing its investigational drug TPST-1120 in combination with atezolizumab and bevacizumab for patients with unresectable or metastatic hepatocellular carcinoma (search) (HCC (search)) who have not previously received systemic therapy. The study aims to determine whether this triple combination can extend patient survival compared to the current standard treatment of atezolizumab and bevacizumab alone.
Novel Mechanism Targets PPARα Pathway
TPST-1120 represents a novel approach to HCC (search) treatment, functioning as an orally administered competitive antagonist of peroxisome proliferator-activated receptor alpha (search) (PPARα (search)). This mechanism of action distinguishes it from existing therapies and may offer synergistic benefits when combined with the established immunotherapy-bevacizumab regimen. The drug is designed to be administered orally, while atezolizumab and bevacizumab are delivered intravenously.
Rigorous Study Design Ensures Data Quality
The Phase 3 trial employs a randomized, parallel assignment design with quadruple masking, ensuring that participants, care providers, investigators, and outcomes assessors remain blinded to treatment allocation. This robust methodology is intended to minimize bias and provide reliable efficacy and safety data for the combination therapy. The study's primary focus is treatment-oriented, specifically targeting survival extension and cancer progression control.
Timeline and Industry Collaboration
The trial is scheduled to begin recruitment on November 4, 2024, though it has not yet started enrolling patients. The involvement of Hoffmann-La Roche as a collaborator underscores the study's potential significance within the oncology sector and suggests confidence in the therapeutic approach from a major pharmaceutical company.
Complementary Research Program
In addition to the Phase 3 trial, Tempest Therapeutics is conducting the Morpheus-Liver study, a Phase II clinical trial sponsored by The University of Texas MD Anderson Cancer Center. This study is evaluating the effectiveness of neoadjuvant plus adjuvant treatment with atezolizumab and bevacizumab in HCC (search) patients, examining whether this approach can extend the time to disease relapse while maintaining acceptable safety profiles. The Morpheus-Liver study is expected to complete in 2025.
Market Implications
The outcomes of both studies could significantly impact Tempest Therapeutics' position in the competitive oncology market. Positive results from the Phase 3 trial may enhance investor confidence and establish the company as a key player in HCC (search) treatment development. The combination of immunotherapy with novel targeted agents represents a growing trend in cancer therapeutics, potentially offering improved outcomes for patients with limited treatment options.
The clinical development program reflects Tempest Therapeutics' broader strategy to leverage immunotherapy approaches for advanced liver cancers, with TPST-1120 serving as a potential differentiating factor in combination regimens. However, as with all clinical trials, the studies carry inherent risks and uncertainties regarding their ultimate success and regulatory approval prospects.